Roche stops pivotal TIGIT trial after Keytruda lands knockout blow at first attempt

Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting the Swiss drugmaker to stop the study and consider changes to the broader program.

The data come from SKYSCRAPER-06, a study that randomized patients to receive either tiragolumab and Roche’s checkpoint inhibitor Tecentriq or Merck & Co.’s Keytruda and chemotherapy. The participants had previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). 

Roche found the survival data favored the Keytruda regimen at the first interim analysis. The assessment of progression-free survival (PFS) generated a hazard ratio of 1.27. A hazard ratio above 1 indicates the control performed better than the investigational treatment. 

Another tiragolumab NSCLC trial, SKYSCRAPER-01, previously found the anti-TIGIT failed to improve PFS, but leaked overall survival data suggested it may be having a positive effect on overall survival (OS)….
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks